Apremilast

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding adults with moderate-to-severe plaque psoriasis (PsO). The LATITUDE phase 3 studies of zasocitinib demonstrated its superiority over placebo on both co-primary endpoints at week 16. A significant response rate was seen as early as week 4, and continued to increase through to week 24. Additionally, the studies met all ranked secondary endpoints compared to both placebo and treatment with apremilast. The safety and tolerability profiles of zasocitinib were found to be comparable with prior studies, and no new safety signals were identified. Psoriasis is a chronic immune-mediated inflammatory disease caused by skin cells multiplying too quickly. PsO is the most common form of psoriasis, and is characterised by patches of itchy, scaly and painful skin. Areas of the body where psoriatic plaques commonly form include the scalp, face, arms and elbows, legs, knees, torso, genitals, nails and in skin folds. As well as causing physical discomfort and pain, PsO can cause embarrassment, anxiety and social isolation. Around 64 million people live with psoriasis worldwide, and about 80-90% of those have PsO. Zasocitinib is an orally administered tyrosine kinase 2 (TYK2) inhibitor that maintains 24-hour inhibition of interleukin-23 and other established disease-driving immune pathways. Takeda is currently studying the safety and efficacy of zasocitinib compared with deucravacitinib in plaque psoriasis, and in phase 3 studies in psoriatic arthritis. Additional studies are also ongoing in Crohn’s disease, ulcerative colitis and vitiligo, and being initiated in hidradenitis suppurativa. Christophe Weber, president and CEO of Takeda, said: “People living with psoriasis continue to seek safe, effective and fast-acting oral therapies. These landmark results support zasocitinib’s promise to become a leading oral treatment option that can deliver clear skin for patients with PsO.”

Jan. 06, 2026 -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare Conference, to take place January 12-15, 2026, in San Francisco, California. Mapi is actively seeking new partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the J.P. Morgan Healthcare Conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly. Mapi utilizes extended-release Depot technologies protected by strong IP to develop lifecycle Management products for innovative and existing commercially successful pharmaceuticals across multiple therapeutic areas. The Company currently has one partnered product covered under a commercialization agreement, GA Depot for Relapsing Forms of Multiple Sclerosis (RMS), and other products for diabetes and schizophrenia which are funded through Phase II results. The Company’s development pipeline also includes an injectable version of cariprazine, developed using Mapi’s Depot technology, which has demonstrated a long-acting release profile, for one monthly injection. It is designed to address an unmet need for patients with schizophrenia, bipolar I and major depression disorders. Mapi recently began enrolling patients in a Phase I/II study as described in ClinicalTrials.gov ID NCT07185815. Mapi is fully integrated in the development of Depot pharmaceuticals and offers partners multiple distinct technologies. The Company has an extensive R&D team with dedicated Depot labs, an experienced clinical team, as well as a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply. Mapi has the capabilities to efficiently develop Depot products by integrating R&D, clinical studies, registration and manufacturing and has a successful track record of improving time to market. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We have a number of compelling partnering opportunities in our current pipeline, including Deutetrabenazine (AUSTEDO® XR) Depot for the treatment of Huntington's disease and tardive dyskinesia, and Anastrazole (Arimidex®) Depot as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer, as well as other candidates. We are seeking to apply our technologies to co-develop Depot drugs with companies that are interested in developing long-acting injectable lifecycle management products." Mapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi’s lead product is GA Depot which is partnered with Viatris (NASDAQ: VTRS) in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for Relapsing Forms of Multiple Sclerosis (RMS). Following successful Phase 3 results GA Depot is currently under FDA review. The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi's portfolio also includes a leading development of Depot drugs for Schizophrenia, GLP-1 for diabetes, weight loss, with innovative intellectual property. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with an API production and aseptic Depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms facilities. Mapi has strong IP positions, filing numerous patent applications for APIs and formulations. For more information, please visit www.mapi-pharma.com The content above comes from the network. if any infringement, please contact us to modify.